TuHURA Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HURA research report →
Price Chart
About the company
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments.
- CEO
- James A. Bianco
- IPO
- 2013
- Employees
- 22
- HQ
- Tampa, FL, US
Get TickerSpark's AI analysis on HURA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $82.20M
- P/E
- -2.80
- Fwd P/E
- 1.39
- PEG
- -0.11
- P/S
- 0.00
- P/B
- 4.80
- EV/EBITDA
- -3.46
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -146.80%
- ROIC
- -104.95%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-31,795,939
- Net Income
- $-30,060,333-38.6%
- EPS
- $-0.63+47.9%
- OCF Growth
- -87.6%
- FCF Growth
- -87.4%
- 52W High
- $3.43
- 52W Low
- $0.41
- 50D MA
- $1.86
- 200D MA
- $2.03
- Beta
- -0.01
- RSI (14)
- 33
- Avg Volume
- 327.59K
No earnings-call transcripts are available for HURA yet.
- Free Float
- 64.3%
- Shares Outstanding
- 63.73M
- Float Shares
- 40.97M
of shares held by institutions
89 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for HURA, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.32M | ▲ 50.10K |
| Vanguard Capital Management LLC | 2.25M | ▼ 16.77K |
| Northern Trust Corp | 1.62M | ▲ 1.32M |
| Blackrock, Inc. | 588.18K | ▼ 101.91K |
| Fifth Third Bancorp | 521.63K | ▲ 521.63K |
| Geode Capital Management, LLC | 472.76K | ▼ 11.46K |
| Millennium Management LLC | 454.54K | ▲ 454.54K |
| Aqr Capital Management LLC | 424.60K | ▼ 182.57K |
| Vanguard Fiduciary Trust Co | 275.58K | ▲ 24.39K |
| Citadel Advisors LLC | 232.32K | ▲ 232.32K |
| State Street Corp | 192.60K | ▲ 4.20K |
| Apollon Wealth Management, LLC | 158.09K | ▲ 1.57K |
Held by 29 ETFs
Biggest fund positions in HURA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Bianco James A. | other | 75,000 |
| May 28, 26 | Bianco James A. | other | 150,000 |
| Feb 12, 26 | Tendler Craig | other | 156,240 |
| Feb 12, 26 | Ng George K | other | 156,240 |
| Feb 12, 26 | MANUSO JAMES S J | other | 156,240 |
| Feb 12, 26 | List Alan | other | 156,240 |
| Feb 12, 26 | Hoffman Robert E. | other | 156,240 |
| Jan 6, 26 | Dearborn Dan | other | 273,696 |
| Jan 6, 26 | Bianco James A. | other | 610,332 |
| Dec 12, 25 | Dearborn Dan | other | 1,531,367 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HURA coverage
Recent articles, reports, and earnings notes.
No research on HURA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HURA report →TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
prnewswire.com · Nov 13
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
prnewswire.com · Nov 4
TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study
marketbeat.com · Oct 26
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
prnewswire.com · Oct 26
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025
prnewswire.com · Oct 13
TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology
prnewswire.com · Oct 5
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
prnewswire.com · Sep 14
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.